Calhoun Cardiology Center

Farmington, CT, United States

Calhoun Cardiology Center

Farmington, CT, United States
SEARCH FILTERS
Time filter
Source Type

News Article | April 7, 2017
Site: www.techtimes.com

Wearable Tech - The Rise Of Smartwatches, FitBands, Smartglasses And More Fitness bands are popular with people who like to keep a daily track of their workouts and calorie intake. The wrist-worn trackers provide accurate fitness details to health conscious users who deploy the wearables. Now, a Fitbit fitness band has saved the life of its owner by detecting a life-threatening condition. According to a CBS News report, the fitness tracker saved the life of 73-year-old Patricia Lauder from Harwinter, Connecticut. Lauder revealed to the publication that she had bought the Fitbit fitness tracker when she decided to lose weight. A few months ago, Lauder noticed breathing issues, which led her to believe that she had contracted pneumonia. However, tests came back negative for the disease. Following the tests, Lauder noticed that her resting heart rate on the Fitbit wearable rose rapidly with each passing day. One day, the Connecticut woman noticed a shortness of breath and checking on her fitness band revealed that her heart rate had spiked to 140. Not taking any chances, Lauder called for an ambulance immediately. CT scans revealed the underlying problem, which she was silently battling. Lauder was diagnosed with two pulmonary embolisms, or blood clots, inside an artery in both her lungs. This severe condition causes an obstruction in the blood flow, and over burdens the heart. The embolisms also led to an enlarged heart. Both the disorders were potentially life threatening and the immediate treatment saved Lauder's life. Doctors prescribed medication which would disintegrate the clots that had formed inside the artery. After consuming these drugs, Lauder's health stabilized. She stated that without the Fitbit band, she would probably never have understood what was wrong with her. "It certainly helped me under the most recent circumstances," stated a relieved Lauder to CBS News. Her doctors too echoed the same thoughts. "I think the fitbit actually helped her decide whether or not this was a serious condition at the time," revealed Dr. JuYong Lee, Lauder's physician and director of vascular and endovascular medicine at Calhoun Cardiology Center. In January 2016, it was reported that 18-year-old Sarah-Jayne McIntosh from Southport, Merceyside, was diagnosed with a heart condition. This came to light after McIntosh noticed significantly high resting heart rate on her Fitbit. The teen stated that she was shocked to find that her heart rate had almost tripled from the normal 84 beats per minute (bpm) to 210 bpm. She contacted emergency services and was rushed to hospital, where doctors diagnosed her heart condition. These incidents show that the fitness bands are not just limited to serve the purpose of measuring calorie intake and loss, these devices are also essential for people to keep an eye on their pulse and heart rate to ensure that everything stays within the normal range. © 2017 Tech Times, All rights reserved. Do not reproduce without permission.


Baker W.L.,University of Connecticut | White W.B.,Calhoun Cardiology Center
US Cardiology | Year: 2012

Objective: To evaluate the efficacy, safety, and clinical role of azilsartan medoxomil, an angiotensin-II receptor blocker (ARB) that recently gained US Food and Drug Administration approval for lowering of blood pressure (BP) in patients with hypertension. Methods: A systematic review of the literature was performed through October 2011 using the keywords and medical subject headings azilsartan, azilsartan medoxomil, TAK-491, TAK-536, and Edarbi. Citations eligible for inclusion were in vitro or in vivo evaluations of azilsartan medoxomil with no restrictions on patient population or indication used. Data related to the patient populations and outcomes of interest were extracted from each citation. Results: Three trials are available in full publication form, with others available only as abstracts. Azilsartan medoxomil 40 mg and 80 mg daily significantly improves both systolic and diastolic BP from baseline compared with placebo, and the 80 mg dose has greater efficacy than other ARBs, including olmesartan 40 mg daily and valsartan 320 mg daily. Improvements in both 24-hour BP using ambulatory monitoring and clinic BPs, as well as a higher proportion of patients reaching goal, have been seen with azilsartan medoxomil. Additional information shows added BP lowering when azilsartan medoxomil is combined with chlorthalidone. Adverse events are similar with azilsartan medoxomil compared to other ARBs and include headache, dizziness, urinary tract infections, and fatigue. Conclusions: Azilsartan medoxomil is a safe and effective ARB with a unique pharmacologic profile compared with other agents, including slowed angiotensin-II type 1 (AT1) receptor dissociation rates and improved receptor specificity. Studies have shown azilsartan medoxomil 80 mg once daily to reduce BP to a greater extent than valsartan and olmesartan, with similar safety and tolerability. © Touch Briefings 2012.


Baker W.L.,University of Connecticut | Nigro S.C.,MCPHS University | White W.B.,University of Connecticut | White W.B.,Calhoun Cardiology Center
Expert Review of Cardiovascular Therapy | Year: 2014

Azilsartan medoxomil (AZL) is the most recently approved angiotensin receptor blocker (ARB) for treating patients with hypertension. A fixed-dose combination product with AZL and the thiazide-like diuretic chlorthalidone (CLD) is now available to treat individuals who require additional blood pressure lowering. For this review, a literature search was conducted using MEDLINE and the keywords and MeSH terms azilsartan, azilsartan medoxomil, chlorthalidone, thiazide, blood pressure and hypertension. References for retrieved articles were also scanned for relevant citations. No language restrictions were used. AZL is structurally related to candesartan and has been shown to provide more potent angiotensin receptor antagonism versus other ARBs. CLD is a thiazide-like diuretic with a longer half-life and greater blood pressure lowering efficacy than hydrochlorothiazide. The combination of AZL plus CLD has superior efficacy to other ARBs alone or in combination with hydrochlorothiazide based on extensive evaluation in clinical trials. This superior efficacy is not offset by a large imbalance in clinically important adverse events. © Informa UK, Ltd.


Sobieraj D.M.,University of Connecticut | White W.B.,University of Connecticut | White W.B.,Calhoun Cardiology Center | Baker W.L.,University of Connecticut
Journal of the American Society of Hypertension | Year: 2013

Tobacco dependence is a potent risk factor for cardiovascular (CV) diseases and, despite known harms of smoking and benefits associated with smoking cessation, approximately 20% of the adult population with CV diseases or hypertension continue to smoke. Extensive research has demonstrated that nicotine replacement, varenicline, and bupropion sustained-release are superior to placebo for short- and intermediate-term smoking cessation. Because of their mechanisms of action, some smoking cessation therapies have been thought to have the potential to increase CV risk, particularly if the pharmacotherapies are taken while individuals are still smoking. Hence, we have analytically reviewed the literature describing the CV effects of therapies for smoking cessation, particularly as they apply to patients with CV disease. © 2013 American Society of Hypertension. All rights reserved.


Campbell P.,Calhoun Cardiology Center | Campbell P.,University of Connecticut | Baker W.L.,Calhoun Cardiology Center | Baker W.L.,University of Connecticut | And 4 more authors.
Journal of the American Society of Hypertension | Year: 2011

Due to observations of increased off-label use of intravenous hydralazine in area hospitals, we studied its use in a university teaching hospital. Patients were prospectively identified between April and October 2010 with a pharmacy order for intravenous hydralazine. Demographic and clinical information, including pretreatment blood pressure (BP), change in BP and heart rate within 2 hours after administration of hydralazine, and adverse events were obtained. Ninety-four patients (mean age, 69 ± 18 years, 48% women, 89% with known hypertension) received 201 intravenous hydralazine doses (mean dose of 11.4 ± 4.3 mg). Only 4 (2%) patients had evidence of an urgent hypertensive condition. Following hydralazine, BP was reduced by 24/9 ± 29/15 mmHg and heart rate increased by 4 ± 13 beats per minute. Changes from baseline in BP were related to baseline BP. Seventeen patients experienced an adverse event, the most common being hypotension (n = 11). Intravenous hydralazine is commonly prescribed for non-urgent cases of hypertension in the hospitalized patient. While changes in systolic BP are related to baseline BP values, they are highly variable, and associated with hypotension. Thus, this agent may not be useful for treating hypertension in many hospitalized patients and may cause harm if used inappropriately. © 2011 American Society of Hypertension. All rights reserved.


Parthasarathy H.K.,Papworth Hospital | Menard J.,French Institute of Health and Medical Research | White W.B.,Calhoun Cardiology Center | Young W.F.,Mayo Medical School | And 6 more authors.
Journal of Hypertension | Year: 2011

Background: Eplerenone is claimed to be a more selective blocker of the mineralocorticoid receptor than spironolactone being associated with fewer antiandrogenic side-effects. We compared the efficacy, safety and tolerability of eplerenone versus spironolactone in patients with hypertension associated with primary aldosteronism. Methods: The study was multicentre, randomized, double-blind, active-controlled, and parallel group design. Following a single-blind, placebo run-in period, patients were randomized 1: 1 to a 16-week double-blind, treatment period of spironolactone (75-225 mg once daily) or eplerenone (100-300 mg once daily) using a titration-to-effect design. To be randomized, patients had to meet biochemical criteria for primary aldosteronism and have a seated DBP at least 90 mmHg and less than 120 mmHg and SBP less than 200 mmHg. The primary efficacy endpoint was the antihypertensive effect of eplerenone versus spironolactone to establish noninferiority of eplerenone in the mean change from baseline in seated DBP. Results: Changes from baseline in DBP were less on eplerenone (-5.6 ± 1.3 SE mmHg) than spironolactone (-12.5 ± 1.3 SE mmHg) [difference, -6.9 mmHg (-10.6, -3.3); P < 0.001]. Although there were no significant differences between eplerenone and spironolactone in the overall incidence of adverse events, more patients randomized to spironolactone developed male gynaecomastia (21.2 versus 4.5%; P = 0.033) and female mastodynia (21.1 versus 0.0%; P = 0.026). Conclusion: The antihypertensive effect of spironolactone was significantly greater than that of eplerenone in hypertension associated with primary aldosteronism. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.


Du J.,Calhoun Cardiology Center | Du J.,University of Connecticut Health Center | Xie J.,Calhoun Cardiology Center | Xie J.,University of Connecticut Health Center | And 9 more authors.
Circulation Research | Year: 2010

Rationale: Cardiac fibrosis contributes to pathogenesis of atrial fibrillation (AF), which is the most commonly sustained arrhythmia and a major cause of morbidity and mortality. Although it has been suggested that Ca 2+ signals are involved in fibrosis promotion, the molecular basis of Ca2+ signaling mechanisms and how Ca2+ signals contribute to fibrogenesis remain unknown. Objective: To determine the molecular mechanisms of Ca2+-permeable channel(s) in human atrial fibroblasts, and to investigate how Ca2+ signals contribute to fibrogenesis in human AF. Methods and Results: We demonstrate that the transient receptor potential (TRP) melastatin related 7 (TRPM7) is the molecular basis of the major Ca2+-permeable channel in human atrial fibroblasts. Endogenous TRPM7 currents in atrial fibroblasts resemble the biophysical and pharmacological properties of heterologous expressed TRPM7. Knocking down TRPM7 by small hairpin RNA largely eliminates TRPM7 current and Ca2+ influx in atrial fibroblasts. More importantly, atrial fibroblasts from AF patients show a striking upregulation of both TRPM7 currents and Ca2+ influx and are more prone to myofibroblast differentiation, presumably attributable to the enhanced expression of TRPM7. TRPM7 small hairpin RNA markedly reduced basal AF fibroblast differentiation. Transforming growth factor (TGF)-β1, the major stimulator of atrial fibrosis, requires TRPM7-mediated Ca2+ signal for its effect on fibroblast proliferation and differentiation. Furthermore, TGF-β1-induced differentiation of cultured human atrial fibroblasts is well correlated with an increase of TRPM7 expression induced by TGF-β1. Conclusions: Our results establish that TRPM7 is the major Ca 2+-permeable channel in human atrial fibroblasts and likely plays an essential role in TGF-β1-elicited fibrogenesis in human AF. © 2010 American Heart Association, Inc.


PubMed | Calhoun Cardiology Center
Type: Journal Article | Journal: Journal of the American Society of Hypertension : JASH | Year: 2011

Due to observations of increased off-label use of intravenous hydralazine in area hospitals, we studied its use in a university teaching hospital. Patients were prospectively identified between April and October 2010 with a pharmacy order for intravenous hydralazine. Demographic and clinical information, including pretreatment blood pressure (BP), change in BP and heart rate within 2 hours after administration of hydralazine, and adverse events were obtained. Ninety-four patients (mean age, 69 18 years, 48% women, 89% with known hypertension) received 201 intravenous hydralazine doses (mean dose of 11.4 4.3 mg). Only 4 (2%) patients had evidence of an urgent hypertensive condition. Following hydralazine, BP was reduced by 24/9 29/15 mmHg and heart rate increased by 4 13 beats per minute. Changes from baseline in BP were related to baseline BP. Seventeen patients experienced an adverse event, the most common being hypotension (n = 11). Intravenous hydralazine is commonly prescribed for non-urgent cases of hypertension in the hospitalized patient. While changes in systolic BP are related to baseline BP values, they are highly variable, and associated with hypotension. Thus, this agent may not be useful for treating hypertension in many hospitalized patients and may cause harm if used inappropriately.


PubMed | Calhoun Cardiology Center
Type: Journal Article | Journal: Psychology and aging | Year: 2013

Many older adults do not meet physical activity recommendations and suffer from health-related complications. Reinforcement interventions can have pronounced effects on promoting behavior change; this study evaluated the efficacy of a reinforcement intervention to enhance walking in older adults. Forty-five sedentary adults with mild to moderate hypertension were randomized to 12-week interventions consisting of pedometers and guidelines to walk 10,000 steps/day or that same intervention with chances to win $1-$100 prizes for meeting recommendations. Patients walked an average of about 4,000 steps/day at baseline. Throughout the intervention, participants in the reinforcement intervention met walking goals on 82.5% 25.8% of days versus 55.3% 37.1% of days in the control condition, p < .01. Even though steps walked increased significantly in both groups relative to baseline, participants in the reinforcement condition walked an average of about 2,000 more steps/day than participants in the control condition, p < .02. Beneficial effects of the reinforcement condition relative to the control condition persisted at a 24-week follow-up evaluation, p < .02, although steps/day were lower than during the intervention period in both groups. Participants in the reinforcement intervention also evidenced greater reductions in blood pressure and weight over time and improvements in fitness indices, ps < .05. This reinforcement-based intervention substantially increased walking and improved clinical parameters, suggesting that larger-scale evaluations of reinforcement-based interventions for enhancing active lifestyles in older adults are warranted. Ultimately, economic analyses may reveal reinforcement interventions to be cost-effective, especially in high-risk populations of older adults.

Loading Calhoun Cardiology Center collaborators
Loading Calhoun Cardiology Center collaborators